Equity Profile

ALNY

ALNYLAM PHARMACEUTIC

Health CareBiotechnology$40.5B

Apr30Thu

Post-Earnings Recap

ReportedQ1-2026Pre-Market8:00 AM EDT

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.76%

Metric	Actual	Expected	Surprise
EPS	$1.99	$1.48	+117.96%
Revenue	N/A	$1.1B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 2.76%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.99	$1.48	+117.96%
Revenue	N/A	$1.1B	N/A

Management Commentary

Tone: Unknown

No transcript is on record, and the analysis is based solely on numerical results.

What It Means

Alnylam Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which led to a positive stock reaction of 2.76%. However, the lack of revenue data and management commentary leaves some uncertainty about the overall financial health and future direction of the company.

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference to treat genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

$1.48

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference to treat genetic diseases. With a market cap of $40 billion, it plays a significant role in the health care sector, particularly in innovative treatments that address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

In the last quarter, Alnylam reported an EPS of $1.25, significantly beating expectations of $0.75. However, the stock declined by 4.28% the following day, indicating some investor caution despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are generally optimistic about Alnylam's upcoming earnings, expecting solid EPS and revenue growth. However, the stock's recent performance suggests that investors may be cautious about future guidance.

Bull Case

If Alnylam exceeds the EPS estimate and shows strong revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in the stock price.

Key Metrics to Watch

EPS

$1.48

Earnings per share is a key indicator of profitability and can influence investor sentiment.

Revenue

$1.1B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Alnylam achieve an EPS of at least $1.48?

This figure is crucial as it sets the benchmark for investor expectations and could significantly impact stock performance.

What guidance will management provide for future revenue growth?

Future revenue guidance will help investors gauge the company's growth trajectory and market potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Alnylam's ability to deliver strong EPS growth due to its recent performance trends and product pipeline advancements.

Supporting Evidence

The company has consistently beaten EPS estimates in the past quarters, indicating a strong operational track record.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant surprise.

Key Risk

If Alnylam's EPS comes in below $1.48, it could lead to a reassessment of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Alnylam can sustain its recent earnings momentum amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $1.60 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.16 would confirm the bear case, suggesting potential challenges in meeting market expectations.

Pre-Earnings Positioning

Options Market

Implied Move

±7.38%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±7.4% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.7%

Calls (10K)P/C Ratio: 0.37Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations and raises guidance, history suggests the stock could rise by around 1.13% on the following day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 1.13% or more, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of RNA interference therapies and their expected market impact.
2Management's commentary on competitive landscape and how it affects future growth.
3Details on sales performance of existing products and any new product launches.
4Insights into operational efficiencies and cost management strategies.
5Guidance on revenue expectations for the next quarter and full year.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Gerdau S.A.

Company Snapshot

Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference to treat genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and can influence investor sentiment.

$1.48

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+157.23%

Avg Stock Reaction

+1.45%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Alnylam exceeds the EPS estimate and shows strong revenue growth, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in the stock price.

Key Metrics to Watch

EPS

$1.48

Earnings per share is a key indicator of profitability and can influence investor sentiment.

Revenue

$1.1B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Alnylam achieve an EPS of at least $1.48?

This figure is crucial as it sets the benchmark for investor expectations and could significantly impact stock performance.

What guidance will management provide for future revenue growth?

Future revenue guidance will help investors gauge the company's growth trajectory and market potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Alnylam's ability to deliver strong EPS growth due to its recent performance trends and product pipeline advancements.

Supporting Evidence

The company has consistently beaten EPS estimates in the past quarters, indicating a strong operational track record.

Options pricing suggests a higher expected move than historical averages, indicating potential for a significant surprise.

Key Risk

If Alnylam's EPS comes in below $1.48, it could lead to a reassessment of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Alnylam can sustain its recent earnings momentum amid competitive pressures and market conditions.

Bull Confirmed If

An EPS of $1.60 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.16 would confirm the bear case, suggesting potential challenges in meeting market expectations.

Pre-Earnings Positioning

Options Market

Implied Move

±7.38%

Historical Avg

±6.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors anticipate volatility around the earnings report.

Options are pricing ±7.4% while ALNY has averaged ±6.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

39.7%

Calls (10K)P/C Ratio: 0.37Puts (8K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 7 of 23 (30%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Alnylam beats expectations and raises guidance, history suggests the stock could rise by around 1.13% on the following day.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.

Miss

If the company misses earnings expectations, history suggests a potential decline of around 1.13% or more, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the pipeline of RNA interference therapies and their expected market impact.
2Management's commentary on competitive landscape and how it affects future growth.
3Details on sales performance of existing products and any new product launches.
4Insights into operational efficiencies and cost management strategies.
5Guidance on revenue expectations for the next quarter and full year.